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Summary
Acute lymphoblastic leukemia (ALL) can be cured with combination chemotherapy in over 75% of children, but the cause
of treatment failure in the remaining patients is unknown. We determined the sensitivity of ALL cells to individual antileuke-
mic agents in 441 patients and used a genome-wide approach to identify 45 genes differentially expressed in ALL exhibit-
ing crossresistance to prednisolone, vincristine, asparaginase, and daunorubicin. We also identified a distinct phenotype
of discordant resistance to asparaginase and vincristine and 139 genes whose expression was associated with this novel
phenotype. The expression of these genes discriminated treatment outcome in two independent patient populations,
identifying a subset of patients with a markedly inferior outcome (37% ± 13% 5 year DFS).S I G N I F I C A N C E
Many children with “good risk” molecular subtypes of acute lymphoblastic leukemia (ALL) are not cured with current treatment, for
reasons that remain largely unknown. To elucidate genomic determinants of treatment outcome, we used a genome-wide ap-
proach to identify genes and gene expression patterns associated with de novo multiple drug resistance of leukemia cells. This
revealed 45 genes associated with crossresistance to four mechanistically distinct antileukemic agents and 139 genes significantly
related to a novel phenotype of discordant resistance to vincristine and asparaginase. The expression pattern of these genes was
also significantly related to treatment outcome. These findings provide insights to the biological basis of de novo multiple drug
resistance and illuminate potential targets for overcoming this cause of treatment failure in childhood ALL.Introduction
Pediatric acute lymphoblastic leukemia (ALL) has long served
as a paradigm for development of curative chemotherapy of
disseminated cancer, with contemporary treatment protocols
achieving long-term disease-free survival (DFS) of 80% (Pui
and Evans, 1998; Pui et al., 2002). This success is, in part,
related to modulating treatment intensity to each patient’s risk
of relapse. Although clinical features (e.g., age, leukocyte count
at diagnosis) and biological characteristics of leukemia cells
(e.g., chromosome number or translocations) are useful prog-
nostic variables to guide treatment intensity, many patients
with good features are not cured and vice versa. Intrinsic (deCANCER CELL : APRIL 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INCnovo) and acquired resistance to multiple antineoplastic agents
represent major obstacles for successful treatment of the re-
maining 20% of patients who are not cured with current ther-
apy (Pui and Evans, 1998; Sonneveld, 2000).
Cellular drug resistance measured in vitro as lethal concen-
tration (LC50) to prednisolone (PRD), vincristine (VCR), and
asparaginase (ASP) in primary leukemic cells isolated from pa-
tients at diagnosis is significantly associated with DFS in chil-
dren with ALL (den Boer et al., 2003; Hongo et al., 1997;
Kaspers et al., 1997; Pieters et al., 1991). The existence of
crossresistance patterns between structurally distinct antileu-
kemic agents (Kaspers et al., 1998) suggests that common
pathways may contribute to cellular drug resistance in pediat-. DOI 10.1016/j.ccr.2005.03.002 375
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city of data on genomic determinants of de novo crossresis-
tance to ALL chemotherapy.
Acquired multiple drug resistance is a cancer phenotype fre-
quently associated with increased drug efflux mediated by
transmembrane transporters (e.g., ABCB1, ABCB4, ABCC1,
ABCG2, and MVP). This acquired phenotype can be induced
in vitro by prolonged exposure to low drug concentrations but
is not a common mechanism of de novo drug resistance in
childhood ALL (den Boer et al., 1998; Pieters and den Boer,
2003; van den Heuvel-Eibrink et al., 2000). Also, drugs that are
not transported by these efflux pumps, such as PRD, dexa-
methasone, and ASP, are essential components of ALL treat-
ment protocols. Therefore, other mechanisms of multiple drug
resistance must be operative when ALL cells exhibit de novo
crossresistance to these agents.
Gene expression profiles were shown to discriminate drug
sensitivity to 232 compounds in the NCI panel of 60 human
cancer cell lines (Staunton et al., 2001) and to nine drugs in 85
human tumor xenografts in mice (Zembutsu et al., 2002). More
recently, the expression of 172 human gene probe sets was
shown to discriminate primary ALL cells that are sensitive or
resistant to one of four antileukemic agents (Holleman et al.,
2004). Little is known, however, about genes that confer de
novo crossresistance of primary ALL cells to multiple antican-
cer agents, a phenotype likely associated with a very poor
prognosis. The current study was therefore undertaken to de-
termine whether genes could be identified that are differentially
expressed in primary B lineage ALL cells that exhibited de
novo crossresistance to two or more widely used antileukemic
agents (i.e., PRD, VCR, ASP, and daunorubicin [DNR]). The
prognostic importance of genes associated with crossresis-
tance was also assessed by determination of their relation to
treatment outcome in two independent patient populations.
Results
Definition of the multiple drug resistance phenotype
De novo sensitivity of leukemia cells to four widely used anti-
leukemic agents was significantly related among 441 children
with diagnosed B lineage ALL (Figure S1 in the Supplemental
Data available with this article online). Principal component
analysis (PCA) was used to reduce the dimensionality of multi-
variate data (four LC50 values for 441 patients) by transforming
the original variables into uncorrelated ones (i.e., the principal
components) that account for decreasing proportions of vari-
ance (Figure 1). Most of the variation was preserved by the first
component (48%), indicating common variation among all four
drugs, with the four coefficients being similar in weight and
direction. The second component explained 24% of the varia-
tion in LC50 values, affecting VCR and ASP by the same weight
but in opposite directions, revealing discordant sensitivity be-
tween these two drugs (Figure 1). Using the weight of the first
and second component, respectively, a crossresistance score
(CR score) and a vincristine-asparaginase score (VCR-ASP
score) was computed for each patient. The Spearman’s rank
correlations between the CR score and the LC50 values for
each drug were all over 0.5 with p < 0.0001 (except for VCR376Figure 1. Principal component analysis and LC50 value coefficients
Principal component analysis (PCA) based on the LC50 value coefficients
for four antileukemic agents in primary ALL cells from 441 patients with B
lineage ALL. Principal component plot, where each sphere represents a
different ALL sample, and the location is based on the first three principal
components using the patients’ LC50 values for the four antileukemic
agents. In A, ALL samples are labeled (see color key) according to the
sum of the LC50 drug resistance score as previously described (Pieters et
al., 1991) (i.e., 1 for sensitive, 2 for intermediate, 3 for resistance per agent;
the sum results in scores of 4 [most cross-sensitive] to 12 [most crossresis-
tant]). In B, ALL samples are labeled (see color key) according to the
asparaginase (ASP) and vincristine (VCR) discordant sensitivity phenotype.
C illustrates percent variance in LC50 values explained by each compo-
nent of the PCA. Each component was computed as a linear combination
of the LC50 values for the four drugs, with the coefficients listed in the bot-
tom panel. For each component (each column), a positive coefficient
indicates a positive correlation between the LC50 values of the drug and
the computed component scores. A drug with higher absolute coefficient
value contributes more to the component and is more correlated with the
component scores.[rho = 0.23, p = 0.01]). The top and bottom quartiles of CR
scores for the 441 patients were used to define patients with
cross-sensitive and crossresistant ALL. Likewise, the top and
bottom quartiles of the VCR-ASP score defined two cohorts of
patients exhibiting discordant resistance to VCR and ASP (i.e.,
ALL cells that were VCR sensitive plus ASP resistant, or those
VCR resistant plus ASP sensitive, respectively). For the 129
patients whose ALL cells were analyzed for gene expression,CANCER CELL : APRIL 2005
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types (CR scores, VCR-ASP scores) were assigned based on
the values used to define these phenotypes in the entire pop-
ulation of 441 patients. Figure S2 shows that the distribution
of CR scores and VCR-ASP scores in the subset of patients
for whom gene expression was performed (n = 129) did not
differ from the entire patient population (n = 441). Figure S3
shows the distribution of LC50 values for each drug for patients
classified according to crossresistance (CR score) or discor-
dant resistance to VCR and ASP (VCR-ASP score).
Crossresistance was significantly related to patient age at
diagnosis, with older patients being more likely to exhibit a
crossresistant phenotype (Table S1; p = 0.002, R = 0.27, Pear-
son correlation). The VCR-ASP discordant resistance was not
related to patient age (p = 0.12, R = 0.14, Pearson correlation),
although there was a tendency for older children to be VCR
sensitive plus ASP resistant. No statistically significant differ-
ence in sex or proportion of patients with white blood cell
counts at diagnosis lower than 50/nl (WBC < 50/nl) was de-
tected between crossresistant and cross-sensitive ALL or be-
tween the two VCR-ASP discordant resistance groups.Figure 2. Hierarchical clustering using genes that discriminate crossresistant and cross-sensitive B lineage ALL patients
Hierarchical clustering using 51 significant probe sets (45 genes and one cDNA). Each column represents an ALL patient labeled across the top with green
circles for cross-sensitive patients (n = 38) and with red circles for crossresistant patients (n = 29). Each row represents a probe set, with the probe set ID,
gene name, gene symbol (GS), and ratio of expression listed for each probe set. The ratio of expression is the median expression level in crossresistant
patients divided by the median level in cross-sensitive patients (ratio > 1 indicates overexpression in crossresistant patients, whereas a ratio <1 indicates
underexpression in crossresistant patients). The “heat map” indicates high (red) or low (green) level of expression relative to the scale shown.CANCER CELL : APRIL 2005Genes differentially expressed in crossresistant ALL
We identified 51 gene probe sets (representing 45 different
known genes and one cDNA clone) that were differentially ex-
pressed in crossresistant and cross-sensitive ALL based on
correlation analysis with the CR score (p < 0.0001; false dis-
covery rate [FDR] = 2.8%; Table S2). The 10-fold crossvalida-
tion using Spearman’s rank correlation with the top 51 probe
sets revealed significant concordance with the observed CR
gene expression score (rho = 0.52; p < 0.0001; Table S3). Hier-
archical clustering using the selected probes sets correctly as-
signed 63 of 67 crossresistant and cross-sensitive cases (Fig-
ure 2). Similarly, when 51 gene probe sets were used, the PCA
correctly clustered the great majority of patients into either the
crossresistant cluster or the cross-sensitive cluster (Figure
S4A). The biological functions of 32 of the 51 genes discrimi-
nating crossresistance are annotated in the Gene Ontology
(GO) database (Figure S5), with a total of 55 annotations (some
genes are assigned to multiple functions). Genes involved in
nucleic acid metabolism, including transcription (most genes),
RNA and DNA processing, and DNA repair, were significantly
overrepresented in the group of genes discriminating crossre-
sistance, accounting for 26% of the crossresistance genes (14377
A R T I C L Eout of 55) compared to 14% of genes on the entire array (p =
0.013).
Genes discriminating discordant resistance
to VCR and ASP
Based on correlation analysis with the second component of
the PCA, we identified 200 probe sets, representing 139 dif-
ferent genes and 13 cDNAs, that discriminated patients whose
ALL cells were VCR sensitive plus ASP resistant (n = 42 pa-
tients) versus VCR resistant plus ASP sensitive (n = 34 patients;
p < 0.00006; FDR = 6.3%). The genes discriminating VCR-ASP
discordant resistance, their Affymetrix ID, gene symbol, and
expression ratio are provided in Table S5. Hierarchical cluster-
ing (Figure 3) correctly grouped 62 of the 76 patients whose
VCR-ASP scores fell into the top or bottom quartiles. PCA de-
picts the clustering of these patients based on the 200 probe
sets that were associated with discordant resistance to VCR
and ASP (Figure S4B).
Genes involved in protein biosynthesis (90 of 200 probe sets)
were overrepresented among genes discriminating discordant
resistance to VCR and ASP. These genes included ribosomal
proteins (77 of 200 probe sets) and translation elongation
factor-related genes (15 of 200 probe sets). These genes were
tightly clustered in one branch of the hierarchical clustering and
were expressed at a higher level in VCR sensitive plus ASP
resistant ALL compared to VCR resistant plus ASP sensitive
ALL. The majority of other functional categories (e.g., transport,Figure 3. Hierarchical clustering of genes discrimi-
nating discordant resistance to VCR and ASP
Hierarchical clustering using 200 probe sets (139
genes, 13 cDNAs). Each column represents an
ALL sample labeled across the top with blue cir-
cles for VCR-sensitive plus ASP-resistant ALL
(VCR-S+ASP-R; n = 42) and with orange circles
for VCR-resistant plus ASP-sensitive ALL (VCR-
R+ASP-S; n = 34). Each row represents a probe
set, and the probe set ID, gene name, gene
symbol (GS), and ratio of expression are pro-
vided in Table S5. The cluster of genes high-
lighted in magenta contains genes predomi-
nantly involved in protein biosynthesis (97 out of
108). The “heat map” indicates high (red) or low
(green) level of expression according to the
scale shown.378cell communication, response to endogenous stimulus) were
underrepresented among the discriminating genes, compared
to the entire genome (Figure S5).
Because protein synthesis can be altered by various mecha-
nisms, we compared expression levels of RAS-MAPK pathway
genes, p53, RB, n-myc, c-myc, cyclin D, PTEN, AKT, and
mTOR/FRAP, none of which were expressed at a significantly
different level in ALL cells that were VCR sensitive plus ASP
resistant versus VCR resistant plus ASP sensitive.
To address the question of general coregulation of protein
synthesis genes, we identified all probe sets on the U133A
microarray that are annotated in the GO database as involved
in the biological process of “protein synthesis” (i.e., 331 probe
sets; 200 unique genes). Of these, only 31% (104 probe sets
representing 59 genes) were related to VCR-ASP discordant
resistance by cluster analysis. Of these, 58% (34 of 59 genes)
or only 17% of protein synthesis genes were significant in the
VCR-ASP discordant resistance analysis.
Because ribosomal proteins are expressed at higher levels
in VCR-sensitive and ASP-resistant ALL, we have computed
the 95% confidence intervals (CI) for the ratios of the VCR-
sensitive plus ASP-resistant versus VCR-resistant plus ASP-
sensitive ALL cells for each of the ribosomal protein genes (77
gene probe sets) that differed significantly (p = 0.00119 to
<0.0001, Student’s t test) between these two VCR-ASP dis-
cordant resistant phenotypes (42 VCR-S + ASP-R versus 34
VCR-R + ASP-S). The 95% CI for the observed ratio for eachCANCER CELL : APRIL 2005
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lowest 95% CI 1.13 to 1.55, variance for the ratio <3%).
Multiple drug resistance in specific subtypes
of B lineage ALL
ALL with the TEL-AML1 or E2A-PBX1 translocation or hyper-
diploid ALL was more likely to be cross-sensitive (Table S1).
ALL with TEL-AML1 or hyperdiploidy were also more likely to
have a favorable VCR-ASP discordant resistance phenotype
(Table S1).
Altogether, 31 of 34 (91%) ASP-sensitive plus VCR-resistant
ALLs were either TEL-AML1 or hyperdiploid ALL (p < 0.0001,
Fisher’s exact test). Notably, however, only 13 (11 genes) of the
200 probe sets that discriminate discordant resistance to VCR
and ASP also discriminate TEL-AML1 or hyperdiploidy from
other ALL subtypes (with top 100 probe sets for each) using
genes that we have previously reported as discriminating these
genetic subtypes (Table S7) (Ross et al., 2003; Yeoh et al.,
2002).
Hierarchical clustering using genes that discriminated the
crossresistance phenotype did not group ALL cases by molec-
ular or lineage subtypes (Figure S6A). However, hierarchi-
cal clustering using the 200 probe sets that discriminatedFigure 4. Disease-free survival among patients with crossresistant versus cross-sensitive B lineage ALL and patients with discordant VCR-ASP sensitivity
A and C depict disease-free survival (DFS) among patients with B lineage ALL based on different gene expression cross-sensitivity scores (CR score). A
represents the 129 COALL/DCOG patients (crossresistant [n = 33], intermediate [n = 63], and cross-sensitive [n = 33]), and C represents the 83 St. Jude
patients (n = 8, n = 65, and n = 10, respectively). B and D depict DFS among patients with B lineage ALL based on different gene expression scores for
discordant sensitivity to vincristine and asparaginase (VCR-ASP score). B represents the 129 COALL/DCOG patients (VCR sensitive plus ASP resistant [VCR-
S+ASP-R], n = 32; intermediate, n = 64; VCR resistant plus ASP sensitive [VCR-R+ASP-S], n = 33), and D represents the 83 St. Jude patients (n = 15, n = 52, n =
18, respectively).CANCER CELL : APRIL 2005VCR-ASP discordant resistance grouped patients based on
ALL subtype, in particular hyperdiploid and TEL-AML1, were
grouped as ASP sensitive and VCR resistant, whereas E2A-
PBX1, MLL-AF4, and BCR-ABL were primarily grouped as
VCR sensitive and ASP resistant (data not shown). Therefore,
to assess potential subtype bias in genes discriminating VCR-
ASP discordant sensitivity, we adjusted the second component
(VCR-ASP score) for the genetic subtypes by linear model and
by analyzing the residuals identified 40 probe sets, the expres-
sion of which were significantly related to the adjusted VCR-
ASP scores (33 different genes, 3 cDNAs; p < 0.0008; FDR =
29.5%; Figures S6B and S6C). Twenty-four (60%) of these
probe sets were among the 200 probe sets discriminating
VCR-ASP discordant resistance. Similar to the analysis without
adjusting for ALL genetic subtype, 53% (21 of 40) of these
genes encode ribosomal proteins (Figure S7).
Comparison with single drug resistance
gene expression patterns
We previously identified gene expression patterns that discrim-
inate ALL cells exhibiting resistance to individual antileukemic
agents: PRD (33 genes, 3 cDNAs), VCR (40 genes, 14 cDNAs),
ASP (35 genes, 10 cDNAs), and DNR (20 genes, 2 cDNAs) (Hol-379
A R T I C L Eleman et al., 2004). Of the 108 unique known genes and 28
cDNA clones (146 probe sets) discriminating single drug resis-
tance, only 15% of genes (16 genes, 18 probe sets) were also
among genes discriminating crossresistance; the overlap of
multiple drug crossresistance and single drug resistance was
12 genes (13 probe sets) for PRD, five genes for DNR, three
genes (four probe sets) for ASP, and no genes for VCR (four of
these 22 probe sets were duplicates; Table S8). The overlap of
genes discriminating VCR-ASP discordant resistance and sin-
gle drug resistance to VCR was 11 genes and three cDNA
clones (15 probe sets), and that to ASP was 28 genes and two
cDNA clones (39 probe sets). There was no overlap in genes
discriminating VCR-ASP discordant resistance and genes dis-
criminating PRD or DNR single drug resistance (Table S9). For
all overlapping genes, the level of expression (over- or underex-
pressed) associated with resistance was concordant between
the single and multiple drug resistance analyses.
Gene expression and treatment outcome
The median follow-up for the 129 patients included in the gene
expression analysis was 4.3 years from diagnosis. Crossresis-
tant patients (i.e., bottom quartile of the gene expression CR
scores) had significantly worse 5 year DFS compared to pa-
tients classified as cross-sensitive (53% ± 10% versus 91% ±
5%; hazard ratio [HR] = 5.99; p = 0.005; Figure 4A and Table
S10A), with the remaining patients having an intermediate out-
come (80% ± 5%). Among patients whose ALL cells were ASP
sensitive plus VCR resistant, 5 year DFS was 93% ± 5%,
whereas 5 year DFS was only 56% ± 9% (HR = 9.04; p =
0.0038; Figure 4B and Table S10A) among patients whose ALL
was VCR sensitive plus ASP resistant. The remaining group
had an intermediate 5 year DFS of 78% ± 6%. The 5 year DFS
of 17 patients with the most unfavorable quartile for both CR
and VCR-ASP gene expression scores was 37% ± 13%, com-Table 1. Multivariable Cox proportional hazards regression analysis of the risk of relapse in relation to known prognostic factors, crossresistance, and VCR-ASP
discordant resistance gene expression scores
COALL/DCOG Patients St. Jude Patients
Variable n HR 95% CI p value n HR 95% CI p value
Age
<10 years 96 1.0a 57 1.0a
>10 years 33 1.57 0.63–3.9 0.34 26 1.3 0.29–5.9 0.73
WBC
<49/nl 91 1.0a 50 1.0a
50–100/nl 20 0.75 0.2–2.75 0.66 16 1.84 0.27–12.18 0.53
>100/nl 18 2.71 1.07–6.83 0.035 17 1.68 0.27–10.38 0.57
ALL subtype
B-other 42 1.0a 27 1.0a
BCR-ABL 5 2.9 0.74–11.4 0.13 8 35.0 4.55–270 0.0006
E2A-PBX1 6 1.19 0.24–5.8 0.83 12 1.73 0.14–21.1 0.67
Hyperdiploid 33 0.48 0.11–2.13 0.33 15 2.68 0.21–34.4 0.45
MLL-AF4 3 21.9 3.85–124.2 0.0005 5 6.77 0.74–61.6 0.09
TEL-AML1 40 0.19 0.04–0.99 0.049 16 0.92 0.05–15.5 0.95
GE score CRb 129 1.03 0.99–1.08 0.16 83 1.28 1.07–1.52 0.0075
GE score VAb 129 1.00 0.99–1.01 0.65 83 0.99 0.97–1.01 0.35
Multivariable Cox regression analysis computed with known prognostic factors (i.e., white blood cell count [WBC]), age at diagnosis, ALL subtype, and both gene
expression scores as a continuous variable for COALL/DCOG and St. Jude patients. Number of patients (n), hazard ratios (HR), p values, and 95% confidence intervals
(95% CI) are shown.
aReference group.
bUsing the gene expression score as a continuous variable. CR, cross-resistance; VA, VCR-ASP.380pared to 85% ± 10% in 14 patients in the best quartile for both
gene expression scores (Figure S9; HR = 6.05; p = 0.0008).
The predictive value of these gene expression scores (CR
and VCR-ASP) was tested in an independent cohort of 83 B
lineage ALL patients who had been treated with these medica-
tions, but according to a different protocol (Total Therapy 13)
at St. Jude Children’s Research Hospital. The patients in this
population defined as cross-sensitive based on their CR gene
expression score had a significantly better outcome (5 year
DFS = 100% ± 0%) than patients with the crossresistant gene
expression score (5 year DFS = 56% ± 17%; HR = 7.76; p =
0.0005; Figure 4C and Table S10B), similar to that observed
in the German Cooperative Study Group for Childhood Acute
Lymphoblastic Leukemia (COALL)/Dutch Childhood Oncology
Group (DCOG) patient population (91% versus 53%). In con-
trast, DFS was not significantly different for VCR-resistant plus
ASP-sensitive ALL compared to VCR-sensitive plus ASP-resis-
tant ALL, for patients treated on the St. Jude protocol (HR =
1.67; p = 0.57; Figure 4D and Table S10B).
Single factor Cox regression analysis indicated that gene
expression scores for crossresistance (high scores indicate
crossresistance; low scores indicate cross-sensitivity) and
VCR-ASP discordant resistance (high scores indicate VCR sen-
sitive + ASP resistant; low scores indicate VCR resistant + ASP
sensitive) were each significantly related to DFS in the study
cohort. In the univariate analyses, the crossresistance gene ex-
pression score was the only variable significantly related to
treatment outcome in both patient cohorts (HR = 5.99, p =
0.0053 [COALL/DCOG]; HR = 7.76, p = 0.0005 [St. Jude]; Table
S10A). Additional variables that were significant in one cohort,
but not the other, included WBC, MLL-AF4 fusion, TEL-AML1
fusion, and VCR-ASP score in the COALL/DCOG population,
and BCR-ABL fusion in the St. Jude cohort.
The cohort of St. Jude patients showed a similar trend for
the CR gene expression score (HR = 7.76; p = 0.0005; TableCANCER CELL : APRIL 2005
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significantly related to treatment outcome in the St. Jude co-
hort (p > 0.5). Of note, in the St. Jude cohort (n = 83) there
were no relapses in children with a low CR score; thus, no HR
could be determined for the low CR-group. Nevertheless, the
high CR gene expression score was significantly related to an
increased risk of relapse when compared to the intermediate
CR score.
The favorable VCR-ASP scores were predominantly in ALL
cells with either the TEL-AML1 fusion or hyperdiploidy, and the
unfavorable scores were predominantly in cells with the BCR-
ABL or MLL-AF4 fusion. The strongest contributing predictor
in the COALL/DCOG cohort in a multivariable Cox regression
analysis that included all known prognostic factors and both
gene expression scores as continuous variables was presence
of the MLL-AF4 fusion, WBC > 100/nl, and presence of the
TEL-AML1 fusion (p = 0.0005, p = 0.035, p = 0.049, respec-
tively; Table 1), followed by the CR score (p = 0.16). The CR
score was the strongest contributing predictor, other than pres-
ence of the BCR-ABL gene fusion in a multivariable Cox re-
gression analysis in the St. Jude cohort (p = 0.0075; Table 1).
The low VCR-ASP gene expression score was not significantly
related to outcome when compared to the high VCR-ASP
score (p = 0.35; Table 1).
The worst group (bottom 33%) defined by PRD, VCR, ASP,
DNR (PVAD) combined single drug resistance score (5 year
DFS: 60% ± 9% [COALL/DCOG; n = 127]; 68% ± 11% [St.
Jude; n = 92]) was used to test whether the crossresistance
gene expression pattern (score) can further significantly dis-
criminate patients at higher and lower risk for relapse (Figure
5). This identified a subgroup that has a significantly worse out-
come, beyond that predicted by the worst single drug resis-
tance gene expression pattern in two independent cohorts of
patients. Patients with high CR scores had a significantly worse
5 year DFS (40% ± 14% [COALL/DCOG; n = 41; p = 0.044];
50% ± 16% [St. Jude; n = 19; p = 0.048]) compared to patients
with low scores (cross-sensitive, 76% ± 11% [COALL/DCOG],
89% ± 11% [St. Jude]). Consistent with findings in the entire
cohort of St. Jude patients, the VCR-ASP discordant resis-
tance score further discriminated patients at higher risk and
lower risk in the COALL/DCOG cohort (87% ± 9% versus
27% ± 14%; p = 0.001), but not in the St. Jude cohort (Figure S9).
Crossresistance genes also discriminate
mercaptopurine resistance
To assess whether the identified crossresistance gene expres-
sion profile is related to resistance to a broader spectrum of
antileukemic agents (thus a more general multiple drug resis-
tance phenotype), we used in vitro sensitivity for mercaptopu-
rine. The crossresistance gene expression score was signifi-
cantly predictive of in vitro resistance of mercaptopurine (n =
51; p = 0.007, Spearman’s rank correlation), tested at St. Jude
in ALL cells from patients enrolled on the Total Therapy 15 pro-
tocol, in addition to mercaptopurine sensitivity tested in chil-
dren of the COALL/DCOG protocols (n = 29; p = 0.0002; Table
S11). Notably, mercaptopurine resistance was not related to
the VCR-ASP discordant resistance gene score (p = 0.54; p =
0.13), and more importantly, no significant association was
found for mercaptopurine resistance with the combined single
drug resistance gene expression scores (PVAD; p = 0.99; p =
0.06) (Holleman et al., 2004) These data indicate that theCANCER CELL : APRIL 2005crossresistance gene expression score (CR) is significantly pre-
dictive of in vitro resistance of other mechanistically distinct
antileukemic agents beyond the four drugs investigated.
Discussion
Although the cure rate of children with ALL is approximately
80%, many patients are not cured with today’s treatment
(Chauncey, 2001; Pui et al., 2004a). Drug resistance is an im-
portant cause of treatment failure, but the responsible mecha-
nisms are largely unknown (Pieters and den Boer, 2003). Sev-
eral studies have shown the existence of crossresistance
patterns among structurally related and structurally unrelated
drugs in ALL (den Boer et al., 2003; Holleman et al., 2003;
Kaspers et al., 1998; Holleman et al., 2004). The extensively
studied multiple drug resistance mechanisms (e.g., ABCC1
[MRP1], MVP [LRP], and ABCB1 [MDR1]) are of limited impor-
tance in ALL, particularly as a mechanism for de novo drug
resistance (den Boer et al., 1998; van den Heuvel-Eibrink et al.,
2000). Thus, insights are needed to understand the genomic
basis of de novo multiple drug resistance in ALL.
Genome-wide analysis of gene expression in human ALL
cells represents a relatively unbiased approach to identify ge-
nomic determinants of drug response and drug resistance
(Cheok et al., 2003; Holleman et al., 2004; Evans and Relling,
2004). In a previous study, we identified genes associated with
resistance to single antileukemic agents, but not genes associ-
ated with multiple drug resistance (Holleman et al., 2004). Be-
cause crossresistance to multiple agents would likely forebode
an inferior prognosis, and a crossresistant phenotype likely in-
volves mechanisms distinct from single drug resistance, the
current study focused on the genomics of multiple drug resis-
tant ALL. To that end, we identified genes that are differentially
expressed in ALL cells that exhibit de novo crossresistance to
four widely used antileukemic agents and assessed their re-
lationship to treatment outcome. Our results in 441 patients
revealed two major components of de novo multiple drug resis-
tance in childhood ALL, a common mechanism of crossresis-
tance to all four drugs and an unanticipated mechanism of dis-
cordant resistance to VCR and ASP. Our findings also revealed
a markedly inferior outcome of patients whose ALL cells exhibit
a gene expression pattern indicative of these two forms of drug
resistance (i.e., the worst CR and VCR-ASP score). Indeed, the
treatment outcome of patients with both types of drug resis-
tance (5 year DFS 37% ± 13%) is worse than the outcome
observed in the worst subgroup previously identified by single
drug resistance gene expression patterns (Figure S9; 5 year
DFS 60% ± 9%) (Holleman et al., 2004). The aim of our prior
study was to discover genes involved in single drug resistance,
by classifying ALL cells as either sensitive or resistant to one
of the four antileukemic agents (intermediates were excluded),
and the combined gene expression score (sum of all four
drugs) was predictive of treatment outcome. In the current
study, the aim was to discover genes involved in multiple drug
resistance using a different statistical method (PCA) on the
LC50 values of four antileukemic agents in a much larger cohort
of patients (n = 441). The first two principal components were
used to find gene expression patterns significantly associated
with these distinct patterns of multiple drug crossresistance.
The 85% difference in genes identified in the two studies re-
flects the distinction between single drug and multiple drug381
A R T I C L EFigure 5. Crossresistance adds predictive value related to DFS to single drug resistance of PRD, VCR, ASP, DNR among patients with ALL
DFS using the COALL/DCOG cohort (n = 127) subdivided into equal groups (1/3) using the combined single PRD, VCR, ASP, DNR (PVAD) resistance score
(A). After stratification by PVAD, the worst group (n = 41) was further divided into equal groups (1/2) by the multiple drug resistance gene expression (CR)
score (B), revealing significant further discrimination by the multiple drug resistance gene expression pattern. Shown is the DFS in St. Jude patients (n = 92),
divided by the single PVAD resistance score defined by the COALL/DCOG cohort (C). After stratification by PVAD gene expression score, the worst group
(n = 19) was further subgrouped (1/2) by the multiple drug resistance (CR) gene expression score (D).resistance. In further support of the distinct nature of our
crossresistance gene pattern, the FDR is much lower, and the
number of gene probe sets is much higher at different α (corre-
lation p value cutoff), if the PCA based on the in vitro sensitivity
data of all 441 patients is used compared to the PCA based
on the in vitro sensitivity data of only 129 patients (Table S2).
Finally, we found that resistance to mercaptopurine, an antileu-
kemic agent not included in the analysis, was significantly re-
lated to the multiple drug crossresistance gene expression
score, but there was no association with the combined single
drug resistance gene expression score. This provides further
evidence that the crossresistance phenotype reflects an intrin-
sic resistance mechanism that relates to multiple antileukemic
drugs, beyond the four drugs we studied, and is distinct from
our prior combined single drug resistance gene expression sig-
nature (sum of PVAD).
The present study identified 45 different genes and one
cDNA clone (51 probe sets), the expression of which was sig-
nificantly related to de novo crossresistance. The genes iden-
tified are involved in pathways that include transcription, trans-
port, and cell cycle maintenance.
The biological and pharmacological relevance of genes dis-
criminating crossresistant ALL is supported by their relation-
ship to DFS in two different cohorts of patients. The 5 year382DFS was only 53% in COALL/DCOG patients whose ALL cells
exhibited a gene expression pattern indicative of crossresis-
tance (top quartile by gene expression score), compared to
91% in patients with cross-sensitive gene expression scores
(bottom quartile). The prognostic significance of genes discrim-
inating crossresistance was confirmed in an independent co-
hort of patients treated with these drugs on a different protocol
at St. Jude Children’s Research Hospital. The 5 year DFS was
only 56% in patients with ALL cells exhibiting a crossresistant
gene expression pattern, compared to 100% in patients with a
cross-sensitive gene expression pattern. The distinct nature of
the crossresistance phenotype and gene expression pattern
was further demonstrated by the ability of the CR gene expres-
sion pattern to further discriminate treatment outcome within
the cohort of patients with the worst outcome as identified by
the combined single drug resistance gene expression pattern
(Holleman et al., 2004). This was evident to two independent
cohorts of patients, treated on separate protocols in the United
States and Europe. Moreover, the CR gene expression pattern
was able to also discriminate de novo sensitivity to mechanisti-
cally distinct thiopurine antileukemic agents, whereas the com-
bined single drug gene expression score (PVAD) was not.
In addition to the crossresistance phenotype, our PCA iden-CANCER CELL : APRIL 2005
A R T I C L Etified a VCR-ASP discordant resistance phenotype as the sec-
ond strongest component of multiple drug resistance. We
found 139 unique known genes and 13 cDNA clones (200
probe sets), the expression of which were significantly related
to VCR-ASP discordant resistance. Patients whose ALL cells
exhibited a pattern of gene expression associated with VCR
sensitivity and ASP resistance were predominately B lineage
ALL that were not hyperdiploid (>50 chromosomes) and did not
carry the TEL-AML1 gene fusion. In contrast, patients whose
ALL cells were VCR resistant and ASP sensitive were com-
monly either TEL-AML1 positive or hyperdiploid, providing in-
sights into why these genetic subtypes of ALL have a favorable
prognosis, in particular their greater sensitivity to ASP (Kaspers
et al., 1995; Ramakers-van Woerden et al., 2000; Stams et
al., 2003).
Seventy-five of the 200 gene probe sets (38%) discriminating
the VCR-ASP discordant sensitivity phenotype encode ribo-
somal proteins. We have previously shown that overexpression
of ribosomal genes is associated with ASP resistance (Holle-
man et al., 2004), but this provides evidence that overexpres-
sion of the same ribosomal protein genes is associated with
increased VCR sensitivity. ASP has been shown to selectively
suppress synthesis of ribosomal proteins at the level of mRNA
translation and targets a common p70 S6K kinase/eukaryotic
initiation factor 4E binding protein 1 signaling pathway in leuke-
mia cells (Iiboshi et al., 1999). ASP has also been shown to
block protein synthesis and to inhibit synthesis of rRNA (Na-
kashima et al., 1976; Story et al., 1993). Overexpression of pro-
tein synthesis genes that are downstream of ASP effects may
therefore protect cells or delay ASP toxicity. Our findings show
that overexpression of ribosomal protein genes has an oppo-
site effect on VCR resistance, and this phenotype is character-
istic of a novel ALL subgroup. Our findings also suggest that,
if ribosomal protein inhibitors reverse ASP resistance, they may
have an opposite effect on VCR sensitivity.
Resistance to econazole and crossresistance to endoplas-
mic reticulum stress-inducing drugs in HL60 cells can be par-
tially reversed by the ribosome-inactivating protein saporin
(Zhang and Berger, 2003), but such strategies have yet to be
tested for reversing ASP resistance. With contemporary ALL
treatment regimens, ASP dose intensity appears to be an im-
portant determinant of treatment response (Silverman et al.,
2001; Silverman and Sallan, 2003). Furthermore, in vivo ASP
resistance is associated with poor treatment outcome (Asselin
et al., 1999). Taken together with our current findings, the ad-
ministration of ribosomal protein inhibitors may be a viable ap-
proach to overcome ASP resistance, but such strategies would
need to be designed to avoid offsetting effects on VCR sensi-
tivity.
The expression of genes discriminating VCR-ASP discordant
resistance was significantly related to treatment outcome in
patients treated on the COALL/DCOG protocols. In these pa-
tients, those with ALL classified as ASP resistant and VCR sen-
sitive had a 5 year DFS of 56%, compared to 93% in patients
whose ALL cells were ASP sensitive and VCR resistant. Inter-
estingly, the VCR-ASP gene expression pattern was not of
prognostic significance in patients treated on the St. Jude pro-
tocol. Why the VCR-ASP discordant phenotype was signifi-
cantly related to treatment outcome in COALL/DCOG proto-
cols but not the St. Jude treatment cannot be explained by
differences in total cumulative dose of ASP. However, theCANCER CELL : APRIL 2005schedule of ASP administration was different in these proto-
cols, with the St. Jude protocol administering ASP 12 to 25
times compared to 5 to 6 times in the COALL and 4 to 13
times in the DCOG protocols (Harms and Janka-Schaub, 2000;
Harms et al., 2003; Pui et al., 2000; Pui et al., 2004b).
The COALL and DCOG protocols also comprise less overall
intensive therapy than the St. Jude protocol. Etoposide was
extensively used in the St. Jude protocol (total of four doses
of 300 mg/m2 during induction and postremission therapy, plus
HR consolidation therapy), whereas etoposide was not used in
COALL/DCOG. In the COALL protocol, the mechanically sim-
ilar drug teniposide (165 mg/m2) was given, but only one dose
was given for low-risk patients, and two doses were given for
high-risk patients. Additionally, cytarabine in the St. Jude pro-
tocols was given in higher doses and for an extended time
period compared to COALL and DCOG. Thus, the COALL/
DCOG protocols rely more heavily on ASP, and consequently
treatment outcome may be more strongly influenced by the
VCR-ASP phenotype.
It is not known whether the expression of genes associated
with the VCR-ASP discordant resistance phenotypes is caused
by the TEL-AML1 gene fusion or hyperdiploidy and is the basis
for their favorable prognosis. Likewise, it is not known whether
overexpression of ribosomal proteins contributes to the favor-
able prognosis of these ALL subtypes when treated on ASP-
intensive protocols (Pui and Evans, 1998; Zaza et al., 2004).
After the VCR-ASP score was adjusted for ALL subtype, the
majority of significant genes were still linked to protein synthe-
sis. Our current findings have identified drug resistance pheno-
types and gene expression patterns that provide insights into
why these ALL subtypes have a better outcome.
In the current study, we only analyzed B lineage ALL pa-
tients, because T lineage ALL cells have a distinct gene expres-
sion profile, and there were too few T-ALL cases for an inde-
pendent analysis (Ross et al., 2003; Yeoh et al., 2002; Holleman
et al., 2004). T lineage ALL is generally more resistant to PRD,
ASP, DNR, and VCR in vitro (Pieters et al., 1998), and the VCR-
ASP discordant resistant gene expression score was signifi-
cantly higher for this subset of patients in the current study
(data not shown). Because T-ALL has a worse prognosis with
many treatment protocols and may have distinct drug resis-
tance mechanisms, it will be important to extend the current
studies to this major ALL subtype.
In summary, the current work has revealed genes that are
expressed at significantly different levels in ALL cells that ex-
hibit crossresistance to four widely used antileukemic agents
and has shown that the expression pattern of these genes in
ALL cells is significantly related to treatment response and is
able to identify a subgroup with an inferior outcome when com-
pared to gene expression patterns associated with single drug
resistance. Furthermore, the current studies have identified a
phenotype of discordant sensitivity to ASP and VCR and re-
vealed a gene expression signature comprising a large number
of ribosomal protein genes that discriminates ALL cells exhibit-
ing discordant sensitivity to these two widely used antileuke-
mic agents. Together, these findings provide insights into de
novo crossresistance of ALL and point to potential strategies
to circumvent these mechanisms of treatment failure.
Experimental procedures
Leukemia samples
Leukemic cells were isolated from bone marrow aspirates or peripheral
blood from 441 patients with diagnosed B lineage ALL, enrolled on the383
A R T I C L EDCOG ALL-9 protocol in the Sophia Children’s Hospital, or the COALL 92
or 97 protocol. In vitro cytotoxicity was determined for PRD, VCR, ASP, and
DNR utilizing the 4 day in vitro MTT drug resistance assay, as we have
previously described (den Boer et al., 2003; Kaspers et al., 1997; Pieters et
al., 1990). For each patient, we determined the lethal concentration to 50%
of leukemia cells (LC50) for each of the four drugs. ALL cells isolated from
bone marrow or peripheral blood samples of a subset of these patients (n =
129) were also analyzed for gene expression, as described below. 147 of
the 441 patients in the LC50 analysis and 127 of the 129 patients in the
gene expression analysis were part of a prior study of single drug resistance
(Holleman et al., 2004). The ALL subtypes (i.e., >50 chromosomes, TEL-
AML1, MLL-AF4, BCR-ABL, and E2A-PBX1) for the 129 patients in gene
expression subset were determined by flow cytometry, PCR, or FISH, as
previously described (Pui and Evans, 1998).
A separate cohort of 83 B lineage ALL patients, treated on the St. Jude
Children’s Research Hospital Total Therapy 13A and 13B protocols, served
as an independent “test set” for the drug resistance gene expression model
and outcome analyses (Ross et al., 2003; Yeoh et al., 2002). Gene expres-
sion in ALL cells was previously reported for all 83 patients (Ross et al.,
2003; Yeoh et al., 2002), and these patients are among the independent
test set for single drug resistance (Holleman et al., 2004). Mercaptopurine
in vitro resistance was determined at St. Jude in 51 patients enrolled on
Total Therapy 15. All patients or their parents (or guardians) provided in-
formed consent, and local institutional review boards approved all pro-
tocols.
Oligonucleotide microarray analysis
Total RNA from leukemia cells of 129 patients treated on the COALL/DCOG
protocols was hybridized to the U133A GeneChip oligonucleotide microar-
rays containing 22,284 probe sets (~12,700 genes), according to the manu-
facturer’s protocol (Affymetrix, Santa Clara, CA). Gene expression signals
were scaled to the target intensity of 2500, using Affymetrix Microarray
Suite (MAS) 5.0 software. Probe sets expressed in less than three percent
of the patients were excluded, leaving 14,550 probe sets for subsequent
analyses. For illustration of the PCA and the hierarchical clustering, we used
GeneMaths 2.1 software (Applied Maths, St. Martens-Latem, Belgium).
Statistical analyses
LC50 values were first standardized within each drug across all 441 patients
to have the mean equal to zero and one standard deviation equal to one.
This permitted analyses across drugs with equal weighting. PCA was ap-
plied to reduce the dimensionality of multivariate data (LC50 values for all
four drugs in all 441 patients) by transforming the original variables into
uncorrelated new ones (the principal components) that account for decreas-
ing proportions of variance. Two scores, crossresistance to all drugs (CR
score) and discordant resistance to VCR and ASP (VA score) were assigned
to each patient, corresponding to the first two (most important) components
of the PCA.
To adjust for ALL subtype, a linear model was fitted for the second com-
ponent of the PCA with genetic subtype, as the covariate and the residues
obtained from the linear model were used as the adjusted VCR-ASP score.
Spearman’s rank correlation was applied to assess the relation between the
CR score or VCR-ASP score and the log-transformed gene expression val-
ues of each probe set. The Spearman’s rank correlation (rho) is commonly
used as the estimate for the association between two continuous variables
and is similar to R2. Probe sets were ranked according to p values, as
computed by the Spearman’s rank correlation. Selection of genes associ-
ated with the CR and VCR-ASP score was guided by the FDR (Storey and
Tibshirani, 2003) and crossvalidation (10-fold). In each of ten iterations of
crossvalidation, a tenth of the samples were left out, and scores were pre-
dicted based on the other 90% of the samples; the observed and the pre-
dicted score were highly correlated and resulted in a high rho, indicating
the predictor was robust. For each patient, the gene expression score was
defined as the weighted average of the expression signal of the top selected
genes, with the weight being the correlation coefficient determined between384the expression of each of the selected genes and the CR or the VCR-ASP
score in 129 children with B lineage ALL.
We determined the over- or underrepresentation of discriminating genes
in functional groups compared to the human genome as represented by all
genes on the U133A chip, using Fisher’s exact test and information pro-
vided by the Gene Ontology Consortium (http://www.geneontology.org/)
and Affymetrix NetAffx (https://www.affymetrix.com/). Through NCBI’s Gene
Expression Omnibus at http://www.ncbi.nlm.nih.gov/geo/, primary data
are accessible (Platform GPL 96; Samples GSM 9653-8, 9694-6, 9698-9,
9701-4, 9707-20, 9723-29, 9733-39, 9741, 9743-51, 9753-55, 9757-62,
9765-7, 9769-73, 9775, 9777-88, 9790-1, 9794-7, 9799, 9801, 9803-4,
9807-12, 9814-19, 9821, 9824-6, 9828-9, 9831, 9833-4, 9836, 9840,
9842,9845-6, 9848-9, 9851, 9862, 9564, 9932-4, 44303-4; Series
GSE2351), and additional information is provided in the Supplemental Data
and at http://www.stjuderesearch.org/data/ALL5/ or http://www.eur.nl/fgg/
kgk/.
Survival analysis methods were used to estimate the probability of DFS
in crossresistant (top quartile), intermediate (middle two quartiles), or cross-
sensitive (bottom quartile) patients, according to the CR gene expression
score defined by the first component of the PCA. Likewise, DFS was com-
pared for patients classified as VCR sensitive plus ASP resistant (top quar-
tile), VCR resistant plus ASP sensitive (bottom quartile), and all others, ac-
cording to the VCR-ASP gene expression score defined by the second
component. The duration of DFS was defined as the time from diagnosis
until the date of leukemia relapse, where any type of leukemia relapse was
considered an event. Second malignancies and death due to other reasons
were censored at the time of occurrence. Time was also censored at the
last follow-up date if no failure was observed. Cox proportional hazards
regression analysis, as modified by Fine and Gray (Fine and Gray, 1999),
was used to assess the association of the CR and VCR-ASP gene expres-
sion score with DFS.
Supplemental data
The Supplemental Data include eleven supplemental tables and nine sup-
plemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/7/4/375/DC1/.
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